Jeffrey Breall, MD
Interventional Cardiology · Indianapolis, INNPI 1831153717
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $20,000 of the $20,957 with a category attached, or 95.4%. Fujifilm Healthcare Americas Corporation accounts for 95.4% of it on its own, with 21 other manufacturers making up the rest. Reporting peaked in 2019 at $20,160 and has fallen 99.3% since, to $133 in 2025.
Across 52 payments — averaging $403.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Fujifilm Healthcare Americas Corporation$20K
- Amgen$136
- Pfizer$102
- Boston Scientific$100
- Medtronic$82
- E.r. Squibb & Sons, L.L.C.$68
- plus $469 from 16 others
Across 10 payments — averaging $93,443 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sanofi US Services Inc.$932K
- Abbott$3K
What the payments were for
- Consulting fees$20,00095%
- Food & beverage$9575%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Fujifilm Healthcare Americas Corporation | 2 | $20,000 |
| Amgen | 7 | $136 |
| Pfizer | 5 | $102 |
| Boston Scientific | 4 | $100 |
| Medtronic(2 entities) | 5 | $82 |
| E.r. Squibb & Sons, L.L.C. | 4 | $68 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 3 | $51 |
| AstraZeneca | 3 | $51 |
| Shockwave Medical, Inc | 2 | $50 |
| Cardiva Medical, Inc. | 2 | $45 |
| Cardiovascular Systems Inc. | 3 | $45 |
| Merck | 2 | $31 |
| Edwards Lifesciences | 1 | $29 |
| Abiomed | 1 | $26 |
| Novo Nordisk | 1 | $23 |
| Terumo Medical Corporation | 1 | $23 |
| Abbott | 1 | $22 |
| ZOLL Circulation Inc | 1 | $18 |
| Teleflex LLC | 1 | $15 |
| Cardinal Health 200 LLC | 1 | $14 |
| Actelion Pharmaceuticals US, Inc. | 1 | $13 |
| Philips North America LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Synapse CV/3D (MI)$12,000
- Synapse Other (MI)$8,000
How this compares
$20,957 in reported general payments places this provider in the 80th percentile of 170 interventional cardiology providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 268 | $344,380 |
| JardianceEmpagliflozin | 59 | $70,802 |
| EntrestoSacubitril/Valsartan | 50 | $64,069 |
| XareltoRivaroxaban | 52 | $58,935 |
| BrilintaTicagrelor | 56 | $53,734 |
| Repatha SureclickEvolocumab | 62 | $46,145 |
| Repatha SyringeEvolocumab | 29 | $44,610 |
| Ezetimibe | 145 | $6,811 |
| Atorvastatin Calcium | 598 | $5,962 |
| Metoprolol Succinate | 404 | $5,242 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 11 | $5,142 |
| Potassium Chloride | 108 | $3,726 |
| ClopidogrelClopidogrel Bisulfate | 269 | $3,434 |
| Nitroglycerin | 122 | $3,055 |
| Torsemide | 121 | $2,636 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $102 | $344,380268 claims |
| AstraZenecaBrilinta | $51 | $53,73456 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 170 interventional cardiology providers in Indiana.
Other interventional cardiology in Indianapolis
- James HermillerIndianapolis$307K
- Woodrow CoreyIndianapolis$262K
- Michael BallIndianapolis$76K
- Anjan SinhaIndianapolis$54K
- Nitesh GadeelaIndianapolis$48K
- George RevtyakIndianapolis$45K
- Scott SharpIndianapolis$41K
- Amrish MalhiIndianapolis$37K
- Sandeep DubeIndianapolis$21K
- Kevin BallIndianapolis$18K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.